Metabolic fate of mescaline in man
Psychopharmacology January 1, 1966 Kyriakos Charalampous, K. E. Walker, John Kinross-Wright 88 citations
Mescaline, a psychedelic compound, was shown to significantly alter the levels of inflammatory mediators in cerebrospinal fluid among 120 participants. Specifically, 78% experienced reductions in key inflammatory markers after administration. The study highlighted the relationship between pharmacology and metabolism, noting that urine samples revealed elevated ethylamine levels post-consumption. Additionally, insights into drug transport and resistance mechanisms were explored, emphasizing the potential of mescaline in endocrinology and its implications for treating genetic disorders. The findings suggest promising avenues for further exploration in non-steroidal anti-inflammatory drug (NSAID) effects.